Microalbuminuria and endothelial dysfunction: Emerging targets for primary prevention of end-organ damage

Journal of Cardiovascular Pharmacology

Volumn 47, Issue SUPPL. 2, 2006, Pages

  Ochodnicky, Peter ^a   Henning, Robert H ^a   Van Dokkum, Richard P E ^a   De Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular disease; Cocoa; Endothelial dysfunction; Flavanols; Microalbuminuria; Predictive value; Primary prevention

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLAVONOID; FOLIC ACID; GLYCOSAMINOGLYCAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; OMEGA 3 FATTY ACID; POLYPHENOL DERIVATIVE; QUINAPRIL; SULODEXIDE; VITAMIN;

ATHEROSCLEROSIS; BIOAVAILABILITY; BLOOD VESSEL PERMEABILITY; CACAO; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIETARY INTAKE; ENDOTHELIAL DYSFUNCTION; FOOD COMPOSITION; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MICROALBUMINURIA; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; VASODILATATION;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; CAPILLARY PERMEABILITY; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; DIET; ENDOTHELIUM, VASCULAR; FLAVONOIDS; HUMANS; KIDNEY FAILURE, CHRONIC; PRIMARY PREVENTION; PROGNOSIS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; VASODILATION; VON WILLEBRAND FACTOR;

EID: 33750357164     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200606001-00009     Document Type: Review

References (129)

1. Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003;87:S24-S31.
2. de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004;66:2109-2118.
3. de Zeeuw D. Albuminuria, just a marker for cardiovascular disease, or is it more? J Am Soc Nephrol. 2005;16:1883-1885.
4. Diercks GF, van Boven AJ, Hillege JL, et al. The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol. 2002;18:525-535.
5. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32:219-226.
6. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89-93.
7. Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430-1432.
8. Marshall SM. Screening for microalbuminuria: which measurement? Diabet Med. 1991;8:706-711.
9. Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens (Greenwich). 2004;6:2-7.
10. Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care. 2000;23(Suppl 2):B35-B39.
11. Savage S, Nagel NJ, Estacio RO, et al. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis. 1995;25:836-844.
12. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med. 1988;5:126-134.
13. Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis. 2004;44:792-798.
14. Bigazzi R, Bianchi S, Campese VM, et al. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron. 1992;61:94-97.
15. Pontremoli R, Sofia A, Ravera M, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Hypertension. 1997;30:1135-1143.
16. Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens. 2002;20:405-412.
17. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519-526.
18. Atkins RC, Polkinghorne KR, Briganti EM, et al. Prevalence of albuminuria in Australia: the AusDiab Kidney Study. Kidney Int Suppl. 2004;92:S22-S24.
19. Garg AX, Kiberd BA, Clark WF, et al. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165-2175.
20. Romundstad S, Holmen J, Kvenild K, et al. Clinical relevance of microalbuminuria screening in self-reported non-diabetic/non-hypertensive persons identified in a large health screening-the Nord-Trondelag Health Study (HUNT), Norway. Clin Nephrol. 2003;59:241-251.
21. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
22. Dinneen SF. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418.
23. Yudkin JS. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988;2:530-533.
24. Jensen J, Feldt-Rasmussen B, Strandgaard S, et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000;35:898-903.
25. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901-906.
26. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol. 1999;19:1992-1997.
27. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
28. Verhave JC, Gansevoort RT, Hillege HL, et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004;92:S18-S21.
29. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:III27-III32.
30. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983-1992.
31. Stehouwer CD. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant. 2004;19:778-781.
32. Goligorsky MS. Endothelial cell dysfunction: can't live with it, how to live without it. Am J Physiol Renal Physiol. 2005;288:F871-F880.
33. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1986;29:282-286.
34. Nannipieri M, Rizzo L, Rapuano A, et al. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients. Diabetes Care. 1995;18:1-9.
35. Jensen JS, Borch-Johnsen K, Jensen G, et al. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (London). 1995;88:629-633.
36. Nannipieri M, Penno G, Rizzo L, et al. Transcapillary escape rate of albumin in type II diabetic patients. The relationship with microalbuminuria and hypertension. Diabetes Care. 1997;20:1019-1026.
37. Pedrinelli R, Penno G, Dell'Omo G, et al. Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension. 1999;34:491-495.
38. Zenere BM, Arcaro G, Saggiani F, et al. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. Diabetes Care. 1995;18:975-982.
39. Dogra G, Rich L, Stanton K, et al. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia. 2001;44:593-601.
40. Yu Y, Suo L, Yu H, et al. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract. 2004;65:95-104.
41. Papaioannou GI, Seip RL, Grey NJ, et al. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol. 2004;94:294-299.
42. Poredos P, Kek A. Relation of blunted dilation of the brachial artery in insulin-dependent diabetes mellitus to microalbuminuria. Am J Cardiol. 2000;86:364-367.
43. Stehouwer CD, Henry RM, Dekker JM, et al. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Study. Kidney Int Suppl. 2004;92:S42-S44.
44. Papaioannou GI, Seip RL, Grey NJ, et al. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol. 2004;94:294-299.
45. Clausen P, Jensen JS, Jensen G, et al. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001;103:1869-1874.
46. Taddei S, Virdis A, Mattei P, et al. Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients. J Hypertens. 1995;13:1003-1008.
47. Diercks GF, Stroes ES, van Boven AJ, et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. Atherosclerosis. 2002;163:121-126.
48. Dogra G, Rich L, Stanton K, et al. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia. 2001;44:593-601.
49. Lim SC, Caballero AE, Smakowski P, et al. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care. 1999;22:1865-1870.
50. Meeking DR, Cummings MH, Thorne S, et al. Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria. Diabet Med. 1999;16:841-847.
51. Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14-18.
52. Gruden G, Cavallo-Perin P, Bazzan M, et al. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes. 1994;43:426-429.
53. Kario K, Matsuo T, Kobayashi H, et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol. 1995;15:1114-1120.
54. Yu Y, Suo L, Yu H, et al. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract. 2004;65:95-104.
55. Ibrahim HA, El Meligi AA, Abdel-Hamid M, et al. Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus. Med Sci Monit. 2004;10:CR85-CR89.
56. Collier A, Rumley A, Rumley AG, et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes. 1992;41:909-913.
57. Kashiwazaki K, Hirano T, Yoshino G, et al. Decreased release of lipoprotein lipase is associated with vascular endothelial damage in NIDDM patients with microalbuminuria. Diabetes Care. 1998;21:2016-2020.
58. Clausen P, Jacobsen P, Rossing K, et al. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet Med. 2000;17:644-649.
59. Schmidt AM, Crandall J, Hori O, et al. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br J Haematol. 1996;92:747-750.
60. Lim SC, Caballero AE, Smakowski P, et al. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care. 1999;22:1865-1870.
61. Agewall S, Lindstedt G, Fagerberg B. Independent relationship between microalbuminuria and plasminogen activator inhibitor-1 activity (PAI-1) activity in clinically healthy 58-year-old men. Atherosclerosis. 2001;157:197-202.
62. Stehouwer CD, Fischer HR, van Kuijk AW, et al. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes. 1995;44:561-564.
63. Verrotti A, Greco R, Basciani F, et al. von Willebrand factor and its propeptide in children with diabetes. Relation between endothelial dysfunction and microalbuminuria. Pediatr Res. 2003;53:382-386.
64. Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319-323.
65. Clausen P, Feldt-Rasmussen B, Jensen G, et al. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study. Clin Sci (London). 1999;97:37-43.
66. Lim SC, Caballero AE, Smakowski P, et al. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care. 1999;22:1865-1870.
67. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
68. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
69. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
70. Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol. 2000;86:207-210.
71. London GM, Pannier B, Agharazii M, et al. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int. 2004;65:700-704.
72. Heitzer T, Baldus S, von Kodolitsch Y, et al. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol. 2005;25:1174-1179.
73. Schindler TH, Hornig B, Buser PT, et al. Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler Thromb Vasc Biol. 2003;23:495-501.
74. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
75. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505-510.
76. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-641.
77. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
78. Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. J Am Coll Cardiol. 2002;39:1133-1138.
79. Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
80. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
81. Jager A, van Hinsbergh VW, Kostense PJ, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes. 2000;49:485-491.
82. Fioretto P, Stehouwer CD, Mauer M, et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia. 1998;41:233-236.
83. Jager A, van Hinsbergh VW, Kostense PJ, et al. Prognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria. Nephrol Dial Transplant. 2001;16:529-536.
84. Klausen KP, Scharling H, Jensen G, et al. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension. 2005;46:33-37.
85. Gschwend S, Buikema H, Navis G, et al. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. J Am Soc Nephrol. 2002;13:2909-2915.
86. Noiri E, Satoh H, Taguchi J, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension. 2002;40:535-540.
87. Akcay A, Sezer S, Ozdemir FN, et al. Association of the genetic polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction. Transplantation. 2004;78:892-898.
88. Asakimori Y, Yorioka N, Tanaka J, et al. Association between ENOS gene polymorphism and cardiovascular events in nondiabetic hemodialysis patients: a prospective study. Am J Kidney Dis. 2004;44:112-120.
89. Jacobsen P, Tarnow L, Carstensen B, et al. Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol. 2003;14:2843-2850.
90. Sakka Y, Babazono T, Sato A, et al. ACE gene polymorphism, left ventricular geometry, and mortality in diabetic patients with end-stage renal disease. Diabetes Res Clin Pract. 2004;64:41-49.
91. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
92. Chaturvedi N, EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
93. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982-988.
94. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-1951.
95. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
96. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-678.
97. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol. 2001;21:449-454.
98. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000;30:980-987.
99. Smulders YM, van Eeden AE, Stehouwer CD, et al. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest. 1997;27:997-1002.
100. Dedov I, Shestakova M, Vorontzov A, et al. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant. 1997;12:2295-2300.
101. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13:1615-1625.
102. Bianchi S. Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. Am J Med. 1992;93:525-528.
103. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
104. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202.
105. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
106. Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000;23:888-892.
107. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
108. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-2816.
109. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
110. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
111. Group Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
112. Arcaro G, Zenere BM, Saggiani F, et al. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care. 1999;22:1536-1542.
113. Schalkwijk CG, Smulders RA, Lambert J, et al. ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. Eur J Clin Invest. 2000;30:853-860.
114. Gasic S, Wagner OF, Fasching P, et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens. 1999;12:217-222.
115. Tan KC, Chow WS, Ai VH, et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev. 2002;18:71-76.
116. Dogra GK, Watts GF, Chan DC, et al. Statin therapy improves brachial artery vasodilator function in patients with type 1 diabetes and microalbuminuria. Diabet Med. 2005;22:239-242.
117. Stoclet JC, Chataigneau T, Ndiaye M, et al. Vascular protection by dietary polyphenols. Eur J Pharmacol. 2004;500:299-313.
118. Mukamal KJ, Maclure M, Muller JE, et al. Tea consumption and mortality after acute myocardial infarction. Circulation. 2002;105:2476-2481.
119. Hertog MG, Feskens EJ, Hollman PC, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342:1007-1011.
120. Duffy SJ, Keaney JF Jr, Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation. 2001;104:151-156.
121. Flesch M, Schwarz A, Bohm M. Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol. 1998;275:H1183-H1190.
122. Lee KW, Kim YJ, Lee HJ, et al. Cocoa has more phenolic phytochemicals and a higher antioxidant capacity than teas and red wine. J Agric Food Chem. 2003;51:7292-7295.
123. Fisher ND, Hollenberg NK. Flavanols for cardiovascular health: the science behind the sweetness. J Hypertens. 2005;23:1453-1459.
124. Keen CL, Holt RR, Oteiza PI, et al. Cocoa antioxidants and cardiovascular health. Am J Clin Nutr. 2005;81:298S-303S.
125. Fisher ND, Hughes M, Gerhard-Herman M, et al. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens. 2003;21:2281-2286.
126. Vlachopoulos C, Aznaouridis K, Alexopoulos N, et al. Effect of dark chocolate on arterial function in healthy individuals. Am J Hypertens. 2005;18:785-791.
127. Grassi D, Lippi C, Necozione S, et al. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr. 2005;81:611-614.
128. Heiss C, Dejam A, Kleinbongard P, et al. Vascular effects of cocoa rich in flavan-3-ols. JAMA. 2003;290:1030-1031.
129. Grassi D, Necozione S, Lippi C, et al. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension. 2005;49:398-405.